Compare H2O America (HTO) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H2O America vs 10X Genomics Inc — how do they compare? H2O America trades at $62.42 (market cap $2.61B), while 10X Genomics Inc trades at $57.08 (market cap $7.61B). The key difference: 10X Genomics Inc is far larger — about 2.9× H2O America's market cap, and H2O America pays a 2.83% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| HTO | TXG | |
|---|---|---|
Market Cap | $2.61B | $7.61B |
Sector | Technology | Health |
52-Week High | $65.43 | $58.57 |
52-Week Low | $44.44 | $11.34 |
Enterprise Value | $4.40B | $7.14B |
Dividend Yield | 2.83% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTO trades at $62.42, up 1.92% in the past 24 hours, with a bullish technical signal from moving averages. The stock shows solid fundamentals with a 12.91% net income margin and consistent earnings beats in recent quarters. Recent news highlights transformative acquisitions in Texas, though dilution risks exist. Institutional interest is strong, with Fifth Third Bancorp increasing its stake by 3,753.2% in Q1 2026 (SEC filing, 2026-07-30).
Outlook is positive with an 83.33% analyst buy rating and a consensus price target of $69.50, implying ~11% upside. Risks include execution challenges from acquisitions and potential EPS pressure from equity issuance. The dividend yield remains supported, but growth sustainability depends on operational efficiency amid expansion.
TXG (10x Genomics) trades at $56.95, down 2.77% on the day. The stock exhibits bullish technical signals with strong moving averages, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and a narrowing net loss margin from -41.23% in 2023 to -12.18% in 2026. Recent news highlights collaborations with Cleveland Clinic and acquisition of Proteintech Genomics, expanding multiomics capabilities.
Outlook: Growth potential exists through market expansion and innovation, but risks include persistent unprofitability and high valuation multiples. Analyst sentiment is mixed with a $46 consensus target below current price, indicating caution despite recent operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About H2O America
H2O America is a utility company that provides essential water and wastewater services, primarily in the United States. The company operates a network of regulated water and wastewater systems, focusing on responsible resource management and high-quality service delivery. HTO aims to expand its operational footprint through acquisitions and internal growth, serving residential, commercial, and industrial customers.
Read more on HTO →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
